Avid Bioservices Inc (CDMO)

[freethemice]

Another reason is that sorafenib doesn't work all that well, but it is better than nothing, and the
only approved therapy for HCC, and works even less in Asian patients. See my post # 77582. So the hope
is that bavi + sorafenib will be a significant improvement. In addition, the rate of HCC is much, much higher
in Asia, due to infection with HBV, than in North America and Europe.